Intellia Therapeutics, Inc.

Intellia Therapeutics is a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company's modular platform advances both in vivo and ex vivo therapies for various diseases. Its lead in vivo product candidates include nexiguran ziclumeran (NTLA-2001) for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. Intellia also has programs targeting immuno-oncology, autoimmune diseases, and other conditions, including delivering gene editing therapeutics to organs outside the liver. Additionally, the company collaborates with partners such as AvenCell Therapeutics for allogeneic universal CAR-T cell therapies, Kyverna Therapeutics for CD19 CAR-T in B cell-mediated autoimmune diseases, ONK Therapeutics for engineered NK cell therapies, and ReCode Therapeutics for cystic fibrosis treatments.

Intellia Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol NTLA. The company's shares are traded in US Dollars (USD), as it is headquartered in the United States. The exchange is one of the major US stock exchanges, providing liquidity and visibility for the company's stock.

Intellia Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies based on genome editing technologies, particularly CRISPR/Cas9. The company's work involves cutting-edge research and clinical development to address diseases with significant unmet medical needs, such as transthyretin amyloidosis and hereditary angioedema.

Intellia Therapeutics is headquartered in Cambridge, Massachusetts, United States. The company was incorporated in 2014 and has since been based in this major biotech hub. Cambridge is known for its concentration of life sciences companies and research institutions, providing a rich environment for innovation and collaboration in genome editing and therapeutic development.

Intellia Therapeutics has established several key collaborations to advance its pipeline. It has a license and collaboration agreement with AvenCell Therapeutics to develop allogeneic universal CAR-T cell therapies. With Kyverna Therapeutics, it is developing an allogeneic CD19 CAR-T cell therapy for B cell-mediated autoimmune diseases. The company also partners with ONK Therapeutics for engineered NK cell therapies for cancer, and with ReCode Therapeutics to develop genomic medicines for cystic fibrosis. Additionally, Intellia has collaboration agreements with Regeneron Pharmaceuticals, SparingVision SAS, and Rewrite Therapeutics, expanding its reach across various therapeutic areas.